The NCI Experimental Therapeutics (NExT) pipeline

The NExT program focuses on translating biomedical research into effective (new) therapies for cancer by providing Discovery and Development resources to bring new agents to the clinic. NExT unites the drug development expertise of the Division of Cancer Treatment and Diagnosis (DCTD) with the dynamic research programs and state-of-the art facilities of the Center for Cancer Research (CCR) at the NIH Clinical Center—the world’s largest hospital devoted exclusively to clinical research.

Through the Chemical Biology Consortium (CBC) and various Participants, the NCI partners with applicant awardees to facilitate a milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents leading towards clinical evaluation and registration.

For more information, please visit:

http://next.cancer.gov/default.htm